middle.news
Avecho advances final insomnia trial stage as global licensing interest builds
9:40am on Wednesday 28th of October, 2026 AEDT
•
Biotechnology
Read Story
Avecho advances final insomnia trial stage as global licensing interest builds
9:40am on Wednesday 28th of October, 2026 AEDT
Key Points
Recruitment resumes for final Phase III insomnia trial cohort
Approximately 320 additional participants expected to enrol
No serious adverse events reported among 244 participants assessed
International licensing discussions continue ahead of BIO-Europe
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Avecho Biotechnology (ASX:AVE)
OPEN ARTICLE